http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Nonlinear Instability of the Two-Dimensional Striation Model About Smooth Steady States
Besse, C.,Degond, P.,Hwang, HJ.,Poncet, R. Marcel Dekker, Inc 2007 Communications in partial differential equations Vol.32 No.7
<P> The two-dimensional striation model consists of a nonlinear system of PDE's which arises in the modeling of the ionospheric plasma. The local-in-time existence of strong solutions is first proved using Banach's fixed point theorem. Then, under physically relevant assumptions, the system is shown to be nonlinearly unstable as soon as it is linearly unstable. Moreover, the instability occurs before the possible blow-up time of the solution. The proof relies on an earlier work of Hwang and Guo (2003). The first step of the proof is to investigate under which conditions the linearized system is unstable and to prove that its spectrum is bounded, by means of a variational formulation. The second one consists in constructing a family of solutions depending on the parameter &dgr; measuring the smallness of the perturbation to the steady-state. Thanks to the boundedness of the linearized spectrum, this family of solutions is shown to be unstable by means of a power series expansion in &dgr;.</P>
Blackhall, Fiona,Kim, Dong-Wan,Besse, Benjamin,Nokihara, Hiroshi,Han, Ji-Youn,Wilner, Keith D.,Reisman, Arlene,Iyer, Shrividya,Hirsh, Vera,Shaw, Alice T. Elsevier 2014 JOURNAL OF THORACIC ONCOLOGY Vol.9 No.11
<P>Introduction: The main objective of the current post hoc analysis was to compare patient-reported outcomes between crizotinib (N = 172) and chemotherapy subgroups (pemetrexed [N = 99] and docetaxel [N = 72]) in previously treated patients with advanced ALK-positive non-small-cell lung cancer, in PROFILE 1007 study (Pfizer; NCT0093283). Methods: Patient-reported outcomes were assessed at baseline, day 1 of each cycle, and end of treatment. General health status was measured using the EuroQol-5D visual analog scale and health utility index scores were assessed using the EuroQol-5D descriptive system. Functioning, lung cancer symptoms, and global quality of life (QOL) were assessed using European Organisation for Research and Treatment of Cancer QLQ-C30 and the QLQ-LC13 lung cancer module. Repeated measures mixed-effects analyses compared overall scores and change from baseline scores, controlling for baseline scores. Results: The overall mean EQ-5D health utility index scores (95% CI) on treatment were significantly greater (p < 0.05) for crizotinib (0.82 [0.79-0.85]) than for chemotherapy (0.73 [0.70-0.77]; 0.74 [0.70-0.79] for pemetrexed and 0.66 [0.58-0.74] for docetaxel). A significantly greater improvement from baseline was observed with crizotinib versus pemetrexed and versus docetaxel treatment groups for general health status, physical functioning, global QOL, dyspnea, fatigue, and pain. Improvement rates for fatigue, cough, pain, dyspnea, and global QOL were significantly greater on crizotinib compared with pemetrexed and docetaxel, respectively. Worsening rates for diarrhea and constipation were higher with crizotinib. Conclusion: The benefits of crizotinib in improving symptoms and QOL are demonstrated regardless of whether the comparator is pemetrexed or docetaxel.</P>
Synthesis, Characterization and Biological Evaluation of Triclosan Grafted onto Cellulosic Fibers
Khaldi Zineb,Nzambe Ta Keki Jean Kerim,Besse Claire,Ouk Tan-Sothéa,Hadj-Bouazza Amel,Zerrouki Rachida 한국섬유공학회 2018 Fibers and polymers Vol.19 No.9
With the increased risk of disease transmissions and cross-infection caused by microorganisms, the control of microbial infections becomes a very important issue in modern societies. Moreover, with the emergence of antibio-resistant bacterial strains, it is necessary to control the bacterial growth. One of ways to limit the bacterial proliferation is to develop antimicrobial surfaces. The present work describes the synthesis process of a direct linking of propargyled Triclosan to a modified Kraft Pulp. Propargylated Triclosan, and azidated Kraft Pulp were linked in the presence of Cu(I) catalyst, a type of Huisgen’s 1,3-dipolar azide-alkyne cycloaddition reaction, leading to the formation of Triclosan linked to kraft Pulp fibers. The modified Kraft Pulp fibers are characterized by Fourier transform infrared spectroscopy (FTIR) and X-ray photoelectron spectroscopy (XPS). This novel material has been investigated for its antibacterial properties against Escherichia coli, Staphylococcus aureus, Bacillus cereus and Pseudomonas aeruginosa. The developed material showed an important antibacterial activity. Although Triclosan is covalently grafted onto Kraft Pulp, its antibacterial properties are maintained.
Cho, Byoung Chul,Dy, Grace K.,Govindan, Ramaswamy,Kim, Dong-Wan,Pennell, Nathan A.,Zalcman, Gerard,Besse, Benjamin,Kim, Joo-Hang,Koca, Goekben,Rajagopalan, Prabhu,Langer, Simon,Ocker, Matthias,Nogai, Elsevier 2018 Lung cancer Vol.123 No.-
<P><B>Abstract</B></P> <P><B>Objectives</B></P> <P>This phase Ib/II study evaluated safety, pharmacokinetics, maximum tolerated dose (MTD), and efficacy of the pan-cyclin-dependent kinase inhibitor roniciclib with cisplatin-etoposide (CIS-ETOP) or carboplatin-etoposide (CARBO-ETOP) in patients with extensive-disease small-cell lung cancer (ED-SCLC).</P> <P><B>Patients and methods</B></P> <P>In this open-label, non-randomized study, patients with previously untreated ED-SCLC received roniciclib twice daily (BID) in a 3 days on/4 days off schedule. Cisplatin 75 mg/m<SUP>2</SUP> or carboplatin (AUC5) dose was administered on day 1, and etoposide 100 mg/m<SUP>2</SUP> on days 1–3, of 21-day cycles. Phase Ib used a dose-escalation design to define the MTD for phase II. Pharmacokinetics were assessed.</P> <P><B>Results</B></P> <P>Forty-three patients received treatment (roniciclib 2.5 mg BID [+ CARBO-ETOP, n = 4; + CIS-ETOP, n = 3] and roniciclib 5 mg BID [+ CARBO-ETOP, n = 24; + CIS-ETOP, n = 12]). The MTD of roniciclib was 5 mg BID with CARBO-ETOP or CIS-ETOP. Common adverse events were nausea (90.7%) and vomiting (69.8%). Roniciclib was readily absorbed following oral administration at the MTD (median t<SUB>max</SUB> 0.5–1 h), with a 30–40% reduction in exposure when co-administered with CARBO-ETOP or CIS-ETOP; administration of roniciclib had no effect on etoposide or platinum pharmacokinetics. The response rate was 81.4% (35/43) overall and 86.1% (31/36) in the pooled roniciclib 5 mg BID population (all partial responses).</P> <P><B>Conclusion</B></P> <P>Roniciclib co-administered with chemotherapy in patients with ED-SCLC demonstrated tolerability, acceptable pharmacokinetics, and promising efficacy. An observed safety signal in a related phase II study resulted in discontinuation of the present study and termination of further roniciclib development.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Phase Ib/II study of ED-SCLC patients treated with roniciclib plus chemotherapy. </LI> <LI> Combination was well tolerated and readily absorbed across all dose combinations. </LI> <LI> No clinically relevant PK interactions were observed upon concomitant treatment. </LI> <LI> Promising efficacy of roniciclib plus chemotherapy, despite low patient numbers. </LI> <LI> Unfavorable benefit/risk balance from another study led to study termination. </LI> </UL> </P>